In this session, James Peyer, PhD, CEO of Cambrian Biopharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starting clinical trials with the first geroprotectors.

An exclusive Q&A with Cambrian Biopharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.

An exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer, Juliette Han.

A review of recent developments and challenges related to selected blood–brain barrier-crossing strategies — with a focus on non- invasive approaches such as receptor-mediated transcytosis and the use of neurotropic viruses, nanoparticles and exosomes — and analysis of their potential in the treatment of CNS disorders.

James Peyer is the Co-Founder and CEO of Cambrian Biopharma, a Distributed Development Company developing therapeutics targeting the biology of aging. Cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss molecular damage, adding healthy years to your life, prevention vs reversal of diseases, and distributed drug companies.

In 2015, The UN declared February 11th the “International Day of Women and Girls in Science." Today marks the sixth celebration of the vital role women and girls play in science, technology and innovation. We are delighted to showcase some of the women whose work we have covered or will be covering and to play our part in promoting women and girls in science.

Cambrian Biopharma, a new type of biotech venture raising $60 million to execute on a model known as the “Distributed Development Company” or “DisCo,” that is, a multi-asset company combining the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics.

A study on John Cunningham virus-like particles (JC VLPs) and their potential use in developing a delivery system for transport of genes and small molecule cargoes across the blood-brain barrier (BBB).

Cambrian Biopharma, a distributed development company, exits stealth mode with the announcement that it has raised $60 million in private financing to develop medicines to extend healthy lifespan.